GlassScriptPhysician profile
Justin Lebenthal
NPI 1255836052
$1,802.23
in general payments reported to CMS, 2019-2025
24 companies · $1,134 in 2025
The $1,134 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $166 · 2023: $128 · 2024: $256 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.68 |
| Education | $270.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $260.27 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Pfizer INC. | $249.41 | 2023-2025 | |
| Lilly USA, LLC | $218.93 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $181.79 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $124.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $102.48 | 2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $79.35 | 2025 | Trodelvy |
| Sobi, INC | $63.84 | 2025 | |
| Glaxosmithkline, LLC. | $63.29 | 2025 | Ojjaara, Blenrep |
| Beone Medicines USA, INC. | $56.35 | 2025 | Brukinsa |
| Merck Sharp & Dohme LLC | $52.63 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $46.52 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $42.95 | 2025 | Pyrukynd |
| Incyte Corporation | $41.05 | 2022-2025 | Jakafi |
| Tactile Systems Technology INC | $29.77 | 2025 | Nimbl, Flexitouch Plus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $29.65 | 2025 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $24.78 | 2024 | Onivyde |
| Geron Corporation | $24.00 | 2025 | Rytelo |
| Astellas Pharma US INC | $21.72 | 2025 | Xtandi |
| Amgen INC. | $21.40 | 2022 | |
| Exelixis INC. | $20.42 | 2025 | Cabometyx |
| Puma Biotechnology, INC. | $17.14 | 2025 | |
| Taiho Oncology, INC. | $15.27 | 2025 | |
| Eisai INC. | $14.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Lebenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.